Patents by Inventor Chenli DING

Chenli DING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240261418
    Abstract: Disclosed are an SOS1 degrading agent and a preparation method therefor and use thereof. Specifically, disclosed is a compound of formula I: S-L-E(I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a small molecule ligand of an E3 ubiquitin ligase complex; and S is the structure shown in S7. The compound of formula I of the present invention can degrade and/or inhibit SOS1 protein in cells, and can be used for the treatment and/or prevention of an SOS1-mediated disease or disorder, or a disease or disorder caused by the interaction of SOS1 with Ras or SOS1 with Rac.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 8, 2024
    Inventors: Zhengqing YE, Yan FENG, Shiqiang LI, Chenli DING, Qiao WANG, Hong WEI, Shuchen XIE
  • Publication number: 20240261417
    Abstract: Disclosed are an SOS1 degrading agent and a preparation method therefor and use thereof. Specifically, disclosed is a compound of formula I: S-L-E (I), wherein L is a linking chain, which links S and E by means of covalent bonds; E is a small molecule ligand of an E3 ubiquitin ligase complex. The compound of formula I of the present invention can degrade and/or inhibit SOS1 protein in cells, and can be used for the treatment and/or prevention of an SOS1-mediated disease or disorder, or a disease or disorder caused by the interaction of SOS1 with Ras or SOS1 with Rac.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 8, 2024
    Inventors: Chenli DING, Shiqiang LI, Qiao WANG, Hong WEI, Shuchen XIE, Zhengqing YE, Yan FENG
  • Publication number: 20220298139
    Abstract: A compound represented by formula I are provided. The stereoisomer, racemate, tautomer, isotopic label, prodrug or a pharmaceutically acceptable salt of the compound, and a pharmaceutical composition containing the compound, a preparation method, and medical use of the compound are further provided. The structure is as shown in formula I.
    Type: Application
    Filed: September 23, 2020
    Publication date: September 22, 2022
    Inventors: Guozhong YE, Chenli DING, Yawen DING, Qian HE, Chaodong WANG